{"paper_id":"05999edd-e0db-4c59-af1d-6e6676a15590","body_text":"Zusammenfassung\nDas ovarielle Überstimulationssyndrom (OHSS) ist ein Krankheitsbild, das in seltenen Fällen im Rahmen einer künstlichen Befruchtung nach Ovulationsinduktion mit humanem Choriongonadotropin (hCG) auftreten kann. Die genaue Pathophysiologie, die zum OHSS führt, ist nach wie vor nicht vollständig geklärt. Vermutet wird eine erhöhte vaskuläre Permeabilität im Bereich der Ovarien und deren umgebender Gefäße. Das zur Ovulationsinduktion verabreichte hCG spielt eine herausragende Rolle, da es die Aktivierung des ovariellen Renin-Angiotensin-Systems induziert. Besonders gefährdet sind junge und schlanke Frauen mit hyperandrogenämischen Zyklusstörungen und polyzystischem Ovarialsyndrom (PCOS). Pathophysiologie, Präventionsmaßnahmen und Behandlungsstrategie werden im Folgenden diskutiert.\nAbstract\nOvarian hyperstimulation syndrome (OHSS) is a relatively rare complication that occurs during in vitro fertilization (IVF) following ovulation induction with human chorionic gonadotropin (hCG). The exact pathophysiology that leads to OHSS is still not fully elucidated. It is presumably due to increased vascular permeability in the area of the ovaries and their surrounding vessels. The hCG administered to induce ovulation likely plays a pivotal role, as it activates the ovarian renin–angiotensin system. Young and slim women with hyperandrogenism and polycystic ovary syndrome (PCOS) are particularly at risk. Pathophysiology, preventive measures, and treatment strategies are discussed in the article.\nSimilar content being viewed by others\nLiteratur\nTsampras N, Palinska-Rudzka K, Alebrahim Y, Craciunas L, Mathur R (2025) Prevention of ovarian hyperstimulation syndrome (OHSS): British Fertility Society policy and practice guideline. Hum Fertil 28(1):2441827. https://doi.org/10.1080/14647273.2024.2441827\nDietrich K, Ludwig M, Griesinger G (Hrsg) (2020) Reproduktionsmedizin, 2. Aufl. Springer, Berlin\nGullo G, Cucinella G, Stojanovic V et al (2024) Ovarian hyperstimulation syndrome (OHSS): A narrative review and legal implications. J Pers Med 14(9):915. https://doi.org/10.3390/jpm14090915\nWallach EE, Navot D, Bergh PA, Laufer N (1992) Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment. Fertil Steril 58:249–261\nNastri CO, Ferriani RA, Rocha IA et al (2010) Ovarian hyperstimulation syndrome: pathophysiology and prevention. J Assist Reprod Genet 27:121–128\nBergh PA, Navot D (1992) Ovarian hyperstimulation syndrome: a review of pathophysiology. J Assist Reprod Genet 9(5):429–438. https://doi.org/10.1007/BF01204048\nWallach EE, Morris RS, Paulson RJ (1994) Ovarian derived prorenin-angiotensin cascade in human reproduction. Fertil Steril 62(6):1105–1114\nDahan MH, Fatemi HM, Polyzos NP, Garcia-Velasco JA (2024) Pathogenesis and management in OHSS. In: Handbook of Current and Novel Protocols for the Treatment of Infertility. Academic Press, S 197–209\nKosaka K, Fujiwara H, Yoshioka S, Fujii S (2007) Vascular endothelial growth factor production by circulating immune cells is elevated in ovarian hyperstimulation syndrome. Hum Reprod 22(6):1647–1651\nGolan A, Ron-El R, Herman A, Soffer Y (1989) Ovarian hyperstimulation syndrome: an updated review. Obstet Gynecol Surv 44:430–440\nAboulghar MA, Mansour RT (2003) Ovarian hyperstimulation syndrome: classifications and critical analysis of preventive measures. Hum Reprod Update 9:275–289\nOlivennes F (2010) Ovarian hyperstimulation syndrome prevention strategies: individualizing gonadotropin dose. Semin Reprod Med 28:463–467\nAndersen AN, Nelson SM, Fauser BCJM et al (2017) Individualized versus conventional ovarian stimulation for in vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial. Fertil Steril 107(2):387–396\nIshihara, Osamu, and Joan-Carles Arce. “Individualized follitropin delta dosing reduces OHSS risk in Japanese IVF/ICSI patients: a randomized controlled trial.” Reproductive biomedicine online 42.5 (2021): 909-918.\nGriesinger G, Schultz L, Bauer T et al (2011) Ovarian hyperstimulation syndrome prevention by GnRH agonist triggering of final oocyte maturation in a GnRH antagonist protocol with a “freeze-all” strategy: a prospective multicentric study. Fertil Steril 95(6):2029–2033\nJiang L, Qiu Y, Xu L, Chang R, He F (2024) Effect of aromatase inhibitors for preventing ovarian hyperstimulation syndrome in infertile patients undergoing IVF: a systematic review and meta-analysis. Reprod Biol Endocrinol 22(1):85\nSiristatidis CS, Papapanou M, Maheshwari A, Vaidakis D (2025) In vitro maturation in subfertile women with polycystic ovarian syndrome undergoing assisted reproduction. Cochrane Database Syst Rev 2:\nHumaidan P, Quartarolo J, Papanikolaou EG (2010) Preventing ovarian hyperstimulation syndrome: guidance for the clinician. Fertil Steril 94(2):389–400\nWang TH, Horng SG, Chang CL et al (2002) hCG-induced ovarian hyperstimulation syndrome is associated with up-regulation of VEGF. J Clin Endocrinol Metab 87(7):3300–3308\nKolibianakis EM, Papanikolaou EG, Tournaye H et al (2007) Triggering final oocyte maturation using different doses of hCG: a randomized pilot study in PCOS patients. Fertil Steril 88(5):1382–1388\nGriesinger G, Diedrich K, Devroey P, Kolibianakis EM (2006) GnRH agonist for triggering final oocyte maturation in GnRH antagonist protocols: a systematic review and meta-analysis. Hum Reprod Update 12(2):159–171\nNardo LG, Cheema P, Gelbaya TA et al (2006) Optimal length of ‘coasting’ in IVF cycles at risk of OHSS. Hum Fertil 9(3):175–180\nZeng C, Shang J, Jin AM et al (2019) The effect of luteal GnRH antagonist on moderate and severe early ovarian hyperstimulation syndrome during in vitro fertilization treatment: a prospective cohort study. Arch Gynecol Obstet 300(1):223–233. https://doi.org/10.1007/s00404-019-05163-3\nSalama KM, Ragab AHM, El Sherbiny MF et al (2017) Sequential E2 levels not ovarian maximal diameter estimates were correlated with outcome of cetrotide therapy for management of women at high-risk of ovarian hyperstimulation syndrome: a randomized controlled study. BMC Womens Health 17:1–9\nSoares SR (2012) Etiology of OHSS and use of dopamine agonists. Fertil Steril 97(3):517–522\nTang H, Mourad SM, Wang A, Zhai SD, Hart RJ (2021) Dopamine agonists for preventing OHSS. Cochrane Database Syst Rev 4:\nAlvarez C, Alonso-Muriel I, García G et al (2007) Implantation is apparently unaffected by the dopamine agonist Cabergoline when administered to prevent ovarian hyperstimulation syndrome in women undergoing assisted reproduction treatment: a pilot study. Hum Reprod 22(12):3210–3214\nRubenfeld ES, Dahan MH (2021) Does the timing of cabergoline administration impact rates of ovarian hyperstimulation syndrome? Obstet Gynecol Sci 64(4):345–352\nPalomba S, Costanzi F, Nelson SM, Caserta D, Humaidan P (2023) Interventions to prevent or reduce the incidence and severity of ovarian hyperstimulation syndrome: a systematic umbrella review of the best clinical evidence. Reprod Biol Endocrinol 21(1):67\nShahhosseini R et al (2025) The Early Versus Standard Administration of Cabergoline to Prevent Ovarian Hyperstimulation Syndrome in Patients with Polycystic Ovary Syndrome Undergoing ICSI Cycles: A Randomized Clinical Trial. Int J Women’s Health Reproduction Sci 2:13\nAuthor information\nAuthors and Affiliations\nCorresponding author\nEthics declarations\nInteressenkonflikt\nZ. Kristof gibt an, dass kein Interessenkonflikt besteht.\nFür diesen Beitrag wurden von den Autor/-innen keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.\nAdditional information\nHinweis des Verlags\nDer Verlag bleibt in Hinblick auf geografische Zuordnungen und Gebietsbezeichnungen in veröffentlichten Karten und Institutsadressen neutral.\nQR-Code scannen & Beitrag online lesen\nRights and permissions\nAbout this article\nCite this article\nKristof, Z. Das ovarielle Überstimulationssyndrom (OHSS). Gynäkol. Prax. 35, 87–92 (2025). https://doi.org/10.1007/s41974-025-00375-9\nAccepted:\nPublished:\nVersion of record:\nIssue date:\nDOI: https://doi.org/10.1007/s41974-025-00375-9","source_license":"CC0","license_restricted":false}